SUNDAY, APRIL 10 Across Societies – Experimental Biology

PHARMACOLOGYC224 619.8 High cocaine locomotor responding rats havegreater hippocampal norepinephrine transporter function thanlow cocaine locomotor responding rats after acute cocaineexposure. T.L. Richards and N.R. Zahniser. Univ. of ColoradoDenver Sch. of Med.C225 619.9 Effects of monoamine releasers varying inselectivity to release dopamine/norepinephrine versus serotoninon choice between cocaine and food in rhesus monkeys. M.L.Banks, B.E. Blough and S.S. Negus. Virginia CommonwealthUniv. and Res. Triangle Inst., NC.C226 619.10 Multiple cocaine unit doses are redundantwhen measuring the magnitude of effect of dopamine receptorantagonists on self-administration. A.B. Norman, M.R. Tabet,M.K. Norman and V.L. Tsibulsky. Univ. of Cincinnati.C227 619.11 Effect of injection duration on the acquisitionof cocaine self-administration in rats: the role of paired stimuli.C.W. Schindler, E.S. Cogan, E.B. Thorndike and L.V. Panlilio.NIDA, NIH, Baltimore.C228 619.12 Involvement of striatal and hippocampalsigma receptors in methamphetamine-induced maladaptation.A.M. Fennell, J. Swant, T. Ansah, J.S. Goodwin and H.Khoshbouei. Meharry Med. Col.C229 619.13 Adult and adolescent sensitivity to amphetaminefollowing early treatment with methotrexate in mice. A.M.Myers, E.B. Bisen-Hersh and E.A. Walker. Temple Univ.620. CHEMOTHERAPY — TARGET-BASEDDIAGNOSTICS AND THERAPEUTICSPosterSUN. 7:30 AM—WASHINGTON CONVENTION CENTER, EXHIBITHALL ABCPresentation time: 12:30 PM-2:45 PMC230 620.1 Repurposing old drugs to discover novelmultidrug resistance modulators for anti-cancer therapy. S.Arora, C. Garcia and A. Gonzalez. Kean Univ., NJ.C231 620.2 MS-based tissue and drug imaging tomonitor 4EBP1 phosphorylation status and drug-induceddephosphorylation in prostate cancer. N.J. Mastrandrea,C. Hattan, J. Gard, R. Nagle, T. Monks and S. Lau. Univ. ofArizona.C232 620.3 The comparative effectiveness of PARP1inhibitors alone or in combination against sporadic cancer. J.De Soto. Appalachain Col. of Pharm., VA.C233 620.4 Insulin resistance-associated hyperinsulinemiaactivates MEK/ERK signaling and promotes prostatic growth:reversal of effect with the intervention of PPARγ agonistpioglitazone. A. Vikram, P. Ramarao and G. Jena. Natl. Inst. ofPharmaceut. Educ. and Res., Mohali, India and Central Univ. ofPunjab.C234 620.5 The C-terminal transmembrane domain andloop region of Bcl-XS are important for its antiapoptotic activities.C.O. Eno, K.E. Olberding and C. Li. Univ. of Louisville.C235 620.6 Tyrosine phosphorylation of HSC70 mayregulate its methotrexate binding properties and multidrugresistance in L1210 murine leukemia cell lines. T. Liu, P.P.Sheridan, A. Bhushan, J.C. K. Lai and C.K. Daniels. IdahoState Univ.C236 620.7 Post-formulation of peptide-nanostructuresfor metered control of NF-κB signaling. H. Pan, O. Ivashyna,B. Sinha, G. Lanza, L. Ratner, P.H. Schlesinger and S.A.Wickline. Washington Univ. Sch. of Med.C237 620.8 Impact of mitochondrial superoxide dismutaseon cytotoxic activity of resveratrol and its hydroxylatedanalogues in HeLa and C33A cancer cell lines. H. Piotrowska,J. Budna, M. Wierzchowski, U. Kazimierczak-Majchrzak, M.Kucinska and M. Murias. Poznan Univ. of Med. Sci., Poland.C238 620.9 Calpain and caspase orchestrated death signalto accomplish apoptosis induced by resveratrol and its novelanalog HST-1 in cancer cells. S.K. Bandyopadhyay, P. Guhaand A. Dey. Dr. BC Roy Post Grad. Inst. of Basic Med. Sci. andIPGME&R, Kolkata, Univ. of Maryland Sch. of Med. and Univ. ofFlorida Col. of Med.C239 620.10 Cancer caveolin status: the dependence ofanesthetic exposure to postoperative cancer chemotherapy ininduction of cell death and survival. S. Okada, Y. Kawaraguchi,P.M. Patel, D.M. Roth and H.H. Patel. UCSD.C240 620.11 Biochemical analysis of a novel dual claudinbinder. Y. Kakamu, K. Matsushita, Y. Saito, A. Takahashi, K.Matsuhisa, A. Watari, M. Kondoh and K. Yagi. Osaka Univ.C241 620.12 A simple screening system for claudin bindersusing an scFv library derived from claudin-immunized mice. M.Kodaka, A. Takahashi, T. Yamaura, Y. Kakamu, K. Matsuhisa,K. Matsushita, A. Watari, M. Kondoh and K. Yagi. Grad. Sch.of Pharmaceut. Sci., Osaka Univ.C242 620.13 Phenol/hydroquinone reduces lymphocytecounts and produces quinol-thioether- and 4-hydroxy-2-nonenal-modifi ed proteins: implications for benzene-mediatedhematotoxicity. C.L. Kuhlman, D.R. Petersen, T.J. Monks andS.S. Lau. Univ. of Arizona and Univ. of Colorado Denver.C243 620.14 Lipid phosphate phosphatase-3 knockdownreduces glioblastoma tumor growth and metastasis bydampening β-catenin signaling. I. Chatterjee and K.K. Wary.Univ. of Illinois at Chicago.621. CHEMOTHERAPY — NATURAL PRODUCTSAND DERIVATIVESPosterSUN. 7:30 AM—WASHINGTON CONVENTION CENTER, EXHIBITHALL ABCPresentation time: 12:30 PM-2:45 PMSUNDAYC244 621.1 Enhanced tumor cures after Foscanphotodynamic therapy combined with the ceramide analogLCL29: evidence from mouse squamous cell carcinomasfor sphingolipids as biomarkers of treatment response. D.Separovic, J. Bielawski, J. Pierce, S. Merchant, A. Tarca,G. Bhatti, B. Ogretmen and M. Korbelik. Wayne State Univ.,Med. Univ. of South Carolina and British Columbia CancerAgcy., Vancouver.C245 621.2 Antimitogenic and chemosensitizing activitiesof syringic acid in human colorectal cancer cells: potentialmolecular mechanisms of action. M.S. I. Abaza, M. Afzal, R.Al-Attiyah, R. Bhardwaj, G. Abbadi and M. Koyippally. Col.of Med., Kuwait Univ.C246 621.3 Antitumorous activity of alpha-bisabololagainst pancreatic cancer. T. Seki, T. Kokuryo, Y. Yokoyama,H. Suzuki, A. Nakagawa and M. Nagino. Nagoya Univ. Grad.Sch. of Med. and Univ. of Verona.180